Assay

High Throughput Screening Market Worth 21.69 Billion USD by 2023

Retrieved on: 
Tuesday, April 24, 2018
Chemistry, Drug discovery, High-throughput screening, Pharmaceutics, High-throughput, Assay, Lab-on-a-chip, HTS, Learning

According to a new market research report "High Throughput Screening Market by Technology (Cell-Based Assays, Lab on a Chip, Bioinformatics), Application (Target Identification, Primary Screening, Toxicology), Product (Reagent, Instruments, Software, Service), End User - Global Forecast to 2023", published by MarketsandMarkets, the market is expected to reach USD 21.69 Billion by 2023 from an estimated USD 14.87 Billion in 2018, at a CAGR of 7.8%.

Key Points: 
  • According to a new market research report "High Throughput Screening Market by Technology (Cell-Based Assays, Lab on a Chip, Bioinformatics), Application (Target Identification, Primary Screening, Toxicology), Product (Reagent, Instruments, Software, Service), End User - Global Forecast to 2023", published by MarketsandMarkets, the market is expected to reach USD 21.69 Billion by 2023 from an estimated USD 14.87 Billion in 2018, at a CAGR of 7.8%.
  • On the basis of product and service, the reagents & assay kits segment accounted for the largest share of the global HTS market.
  • Based on technology, the HTS market is segmented into cell-based assays, lab-on-a-chip (LOC), ultra-high-throughput screening (uHTS), label-free technology, and bioinformatics.
  • Know more about the High Throughput Screening Market:
    MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.

Biomarker Technologies Market Worth 74.51 Billion USD by 2022

Retrieved on: 
Monday, May 7, 2018
Biology, Nature, Biotechnology, Biochemistry, Biomarker, Biomarkers, Chemical pathology, Agilent Technologies, Assay, Biomarker discovery

By product type, the Biomarker Technologies Market is classified into consumables, instruments, services, and software/informatics.

Key Points: 
  • By product type, the Biomarker Technologies Market is classified into consumables, instruments, services, and software/informatics.
  • The clinical diagnostics segment is expected to grow at the highest CAGR in the Biomarker Technologies Market for liquid biopsy during the forecast period.
  • By application, the Biomarker Technologies Market for liquid biopsy is divided into clinical diagnostics, research, and drug discovery and development.
  • By type of profiling technology, the Biomarker Technologies Market is divided into immunoassay, PCR, imaging technology, mass spectrometry, NGS, chromatography, cytogenetics, and other technologies.

2 Day Seminar: Designing & Sustaining New & Existing Product Stability Testing Program (Orlando, FL - June 7-8, 2018)

Retrieved on: 
Friday, April 20, 2018
Software testing, Psychometrics, Assay, Biochemistry, Titration, Statistical hypothesis testing, Measurement, Product, Nature

Performing an effective sampling plan and utilizing the appropriate sample size for a stability testing program.

Key Points: 
  • Performing an effective sampling plan and utilizing the appropriate sample size for a stability testing program.
  • Performing a compliant sample analysis, handling and effecting the appropriate test specification for the product type.
  • How to Effectively Handle, Manage Data, Utilize and Perform the Trending of Stability Testing Results and Data.
  • Knowledge Base: Attendees will gain an understanding in the following key areas:
    How to perform Quality Control Testing, Setting Test Specification and Assay Release Process in a Stability Testing Program.

Roche receives FDA clearance for cobas® CT/NG for cobas® 6800/8800 Systems

Retrieved on: 
Monday, April 16, 2018
RTT, Cobas, Sexually transmitted infection, Assay

cobas CT/NG is the first assay available in the US for the testing of sexually transmitted infections on the cobas 6800/8800 Systems.

Key Points: 
  • cobas CT/NG is the first assay available in the US for the testing of sexually transmitted infections on the cobas 6800/8800 Systems.
  • Other STI assays are in development and will further allow laboratories to consolidate high volume STI testing on a single platform.
  • In addition to cobas CT/NG, cobas 6800/8800 Systems menu in the US includes viral load monitoring tests for HIV, HBV, HCV and CMV, as well as MPX, WNV, DPX and Zika for use in screening blood donations.
  • The systems also enable up to eight hours (cobas 6800 System) and four hours (cobas 8800 System) of walk-away time with minimal user interaction.

Guardant Health to Present Validation Data for the GuardantOMNI™ assay

Retrieved on: 
Friday, April 13, 2018
Assay, Biochemistry, Titration

The validation study demonstrates that, across SNVs, CNVs, fusions, and indels, the performance of the 500-gene GuardantOMNI assay is comparable to the performance of the 73-gene Guardant360 assay, the leading clinical comprehensive liquid biopsy.

Key Points: 
  • The validation study demonstrates that, across SNVs, CNVs, fusions, and indels, the performance of the 500-gene GuardantOMNI assay is comparable to the performance of the 73-gene Guardant360 assay, the leading clinical comprehensive liquid biopsy.
  • Guardant Health and its collaborators will present eight total abstracts at AACR, demonstrating advances in the understanding of cancer biology and innovations in bioinformatics.
  • Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics.
  • Guardant Health and Guardant360 are registered trademarks of Guardant Health, Inc.